Information
Address

Gustave Roussy
114, rue Édouard-Vaillant
94805 Villejuif Cedex - France
Switchboard:

Switchboard

+33 (0)1 42 11 42 11

GUSTAVE ROUSSY
1st cancer center in Europe

© 2006-2015 Gustave Roussy – All rights reserved

CSET 3281

back to job offer list
back to clinical trials

Le carcinome urothélial de vessie (CUV) est une tumeur urologique fréquente, dont le pronostic, au stade avancé, est mauvais.

CSET 3268

back to job offer list
back to clinical trials

Les patients avec des métastases limitées en nombre et en site, « oligométastatique », pourraient être guéris avec des thérapies locales ablatives. La radiothérapie corporelle stéréotaxique (SBRT) permet le traitement de patients opérables et inopérables, avec peu d'effets secondaires. Plusieurs essais randomisés de phase II dans le cadre oligométastatique ont été rapportés, certains d'entre eux montrant un bénéfice de survie globale avec un profil d'effets secondaires bénéfiques.

Nomination Pr Barlesi
08/04/2021

Professor Fabrice Barlesi is appointed General Director of Gustave Roussy

By an order, the Minister of Health and Solidarity, Mr. Olivier Véran, appointed Professor Fabrice Barlesi as General Director of Gustave Roussy for a term of five years from 1 August 2021. He succeeds Professor Jean-Charles Soria who will leave his position for family reasons. Professor Barlesi’s appointment ensures that Gustave Roussy will...

Professor Fabrice Barlesi is appointed General Director of Gustave Roussy

back to job offer list
back to clinical trials

Villejuif, July 30 2021

Professor Fabrice Barlesi is appointed General Director of Gustave Roussy

By an order, the Minister of Health and Solidarity, Mr. Olivier Véran, appointed Professor Fabrice Barlesi as General Director of Gustave Roussy for a term of five years from 1 August 2021. He succeeds Professor Jean-Charles Soria who will leave his position for family reasons. Professor Barlesi’s appointment ensures that Gustave Roussy will continue to work together to develop an ambitious new institutional strategic plan.

Plateforme Cellules Circulantes Rares - Publications

back to job offer list
back to clinical trials

Major publications

Rare circulating cells - Team members

back to job offer list
back to clinical trials

Team members

  • Head of the platform
    Françoise Farace, PhD/HDR
    Email

  • Engineer
    Patrycja Pawlikowska, PhD,

  • Engineer
    Marianne Oulhen

  • Technician
    Agathe Aberlenc

  • PhD student
    Tala Tayoun

     

 

Rare circulating cells - Equipments

back to job offer list
back to clinical trials

Equipment

  • CellSearch platform for CTC and CEC enrichment and detection
  • ISET filtration enrichment system for rare circulating cells (RareCells)
  • Parsortix enrichment microfluidic system for CTCs (Angle) 
  • VyCAP system for rare cell filtration 
  • Automated filtration system Versant kPCR for rare cells (Siemens) 
  • ARIOL scanner (LEICA microsystems) 
  • ARIOL stations for microscopy image analysis (LEICA microsystems)
  • Fluorescence microscope (Nikon)
  • Laser microdissecteur (LEICA microsystems)

Rare circulating cells Platform

back to job offer list
back to clinical trials

Activities

The platform is dedicated to the analysis of rare blood cell components such as circulating tumor cells (CTC) and circulating endothelial cells / progenitors (CEC / CEP), used as biomarkers in clinical trials.

Pages